ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)

Starting soon

Conditions studied: Cancer

In brief

This is a prospective observational study that will collect blood samples at 1-10 timepoints related to initiation of immunotherapy. The study may collect samples before the start of immunotherapy and/or at clinically significant timepoints during immunotherapy treatment.

Key facts

Study ID

NCT06900296

Run by

Indiana University

People needed

100

Starts

2028-01-01

Expected to finish

2029-04-01

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years old at the time of informed consent.
• Have a diagnosis of cancer and initiating therapy with single agent or combination therapy that includes an immunotherapy (see Appendix 16.1 for list of immunotherapy classes).
• Ability to provide written informed consent and HIPAA authorization.

You may not qualify if…

• Not meeting any of the previously described inclusion criteria.

Where it is running

• Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.